NANUET, N.Y., Oct. 4 /PRNewswire/ -- Oren Levy, M.D., Ph.D., analyst for independent research provider White Mountain Capital, LLC, reiterated his BUY rating on Nabi Biopharmaceuticals (NasdaqNM: NABI) ahead of the release of Phase III trial data for the Florida-based biotech company's lead candidate, StaphVAX. "StaphVAX is the key determinant of Nabi's growth and development. As such, the upcoming phase III data release is critical," Levy said. "In our view, StaphVAX is a very promising late-stage candidate because it targets a significant unmet medical need and already has strong efficacy data from one phase III trial." StaphVAX is a vaccine designed to elicit a protective immune response against the most common strains of Staphylococcus aureus ("Staph"). Staph is a major cause of acquired infections in chronically ill patients and is the most-commonly-isolated bacterial pathogen in hospital-acquired infections. If approved, StaphVAX would represent the first preventative approach to the treatment of Staph. To obtain a copy of the report, call toll-free 866-833-5300 during market hours. About White Mountain Capital White Mountain Capital is a full-service broker-dealer in New York. Through its Biotechnology Research Department headed by Dr. Levy, the firm issues independent research on select biotechnology companies. Dr. Levy employs a proprietary research methodology whereby ratings are based strongly on the viability and medical necessity of companies' pipeline projects. CRD #104123. DISCLOSURE INFORMATION The material in White Mountain Capital's reports is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy or completeness. More information or supporting materials may be obtained by calling White Mountain Capital toll-free at 866-833-5300. We certify that the evaluation and opinions in this report are an accurate reflection of the author's opinion about the company covered. The researcher who prepared this report, and whose name appears on the front cover of the report, certifies that the views expressed in the report accurately reflect the author's personal views about the subject company at the time of publication. White Mountain Capital's researchers' compensation is not tied in any way to ratings issued or stock performance of covered companies. Neither White Mountain Capital nor the authoring analyst of any report was paid or given any compensatory consideration by Nabi Biopharmaceuticals to issue this report. White Mountain Capital, LLC initiated coverage on Nabi Biopharmaceuticals on 08/07/02 with a BUY rating. White Mountain Capital does not make a market in this stock. White Mountain Capital has not participated in any investment banking activities with subject company within the past 12 months, nor does it anticipate participating or seeking participation in investment banking activities within the next 3 months. No White Mountain Capital employee or household members of any employee are a director, officer or advisor of the covered company. White Mountain Capital's affiliate, CLG Financial Corp, as well as two non-director board members, have held long positions in the covered company for more than one year. Neither White Mountain Capital nor any of its affiliates beneficially own 1% or more of any class of securities of the subject company. RATING DISCLOSURES (As of 10/04/05) RATING DEFINITION % OF COVERAGE BUY Outstanding company with an appropriate 33% (4/12) valuation, or a company we feel is significantly undervalued. HOLD Good company that is appropriately valued 50% (6/12) or an outstanding company that is somewhat overvalued. SELL Company that has significant weakness or 17% (2/12) is significantly overvalued. White Mountain Capital has not performed investment banking services for any of the companies under coverage. DATASOURCE: White Mountain Capital, LLC CONTACT: Stephen J. Callahan, Managing Director of Sales, +1-845-623-5959 x282, or Renee L. Luchkiw, Supervisor of Research, +1-845-623-5959 x284, both of White Mountain Capital, LLC Web site: http://www.whitemountaincapital.com/

Copyright